Home
About Leecan
Overview of Leecan
History
Corporate Culture
Honor
Responsibility
Product
Marketed Products
Regulatory Review
In Development
Production and Research Platform
Research and Development Platform
Production and Operation
Quality Assurance
CMO/CDMO
News regulations
Investor
Careers
Talent Concept
People in leecan
Recruitment
Career development
Contact Us
Cooperation
Supplier Cooperation
Recruitment
Pharmacovigilance
CMO/CDMO
EN
/
CN
Home
About Leecan
Overview of Leecan
History
Corporate Culture
Honor
Responsibility
Product
Marketed Products
Regulatory Review
In Development
Production and Research Platform
Research and Development Platform
Production and Operation
Quality Assurance
CMO/CDMO
News regulations
Investor
Careers
Talent Concept
People in leecan
Recruitment
Career development
Contact Us
Cooperation
Supplier Cooperation
Recruitment
Pharmacovigilance
CMO/CDMO
Issue 11: Key Updates in Medical and Pharmaceutical Regulations for Early to Mid-2026
Release time：2026-07-08
share:
Previous article：Issue 12: Quick Overview of NMPA/CDE Regulations for May-June
next article：Issue 10: Focusing on the Latest Core Regulations for Drug Review and Pricing
Back to list
You may also want to read
The first "Quality Month" of Leecan has successfully concluded
2024.11.04
Expert group from Anhui Provincial Institute for Food and Drug Control and Evaluation Inspection Center visited Hefei Leecan Pharmaceutical for assistance and guidance
2025.01.03
Two specifications of bendamustine hydrochloride for injection have obtained drug production approval!
2025.01.06
